Incidence and Outcomes of SARS-CoV-2 Infection in Older Adults Living with Dementia: A Population-Based Cohort Study.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2022
Historique:
pubmed: 2 8 2022
medline: 21 9 2022
entrez: 1 8 2022
Statut: ppublish

Résumé

The identification of risk factors for SARS-CoV-2 infection and mortality in patients with dementia is a key aspect to support clinical decisions and public health interventions. To assess the incidence of SARS-CoV-2 infection and COVID-19 related death in a cohort of patients with dementia residing in the Lazio region and to investigate predicting factors for both infection and mortality. This population-based study used information from administrative databases and the SARS-CoV-2 infection surveillance system. Patients with dementia (age ≥65) were enrolled as of December 31, 2019 and followed-up until February 28, 2021. Cumulative risk of infection and death within 60 days of infection onset, and age-standardized incidence (SIR) and mortality (SMR) ratios were calculated. Logistic regression models were applied to identify factors associated with infection and mortality. Among 37,729 dementia patients, 2,548 had a diagnosis of SARS-CoV-2 infection. The crude risk of infection was 6.7%. An increase in risk of infection was observed both in women (SIR 1.72; 95% CI 1.64-1.80) and men (SIR 1.43; 95% CI 1.33-1.54). Pneumonia, cerebrovascular and blood diseases, femur fracture, anxiety, antipsychotic and antithrombotic use were associated with an increased risk of infection. The crude risk of death was 31.0%, the SMRs 2.32 (95% CI 2.05-2.65) for men, and 2.82 (95% CI 2.55-3.11) for women. Factors associated with mortality included: male gender, age ≥85, symptoms at the diagnosis, antipsychotic and systemic antibiotics treatment. These findings emphasize the need of close and tailored monitoring of dementia patients to reduce the impact of COVID-19 on this fragile population.

Sections du résumé

BACKGROUND
The identification of risk factors for SARS-CoV-2 infection and mortality in patients with dementia is a key aspect to support clinical decisions and public health interventions.
OBJECTIVE
To assess the incidence of SARS-CoV-2 infection and COVID-19 related death in a cohort of patients with dementia residing in the Lazio region and to investigate predicting factors for both infection and mortality.
METHODS
This population-based study used information from administrative databases and the SARS-CoV-2 infection surveillance system. Patients with dementia (age ≥65) were enrolled as of December 31, 2019 and followed-up until February 28, 2021. Cumulative risk of infection and death within 60 days of infection onset, and age-standardized incidence (SIR) and mortality (SMR) ratios were calculated. Logistic regression models were applied to identify factors associated with infection and mortality.
RESULTS
Among 37,729 dementia patients, 2,548 had a diagnosis of SARS-CoV-2 infection. The crude risk of infection was 6.7%. An increase in risk of infection was observed both in women (SIR 1.72; 95% CI 1.64-1.80) and men (SIR 1.43; 95% CI 1.33-1.54). Pneumonia, cerebrovascular and blood diseases, femur fracture, anxiety, antipsychotic and antithrombotic use were associated with an increased risk of infection. The crude risk of death was 31.0%, the SMRs 2.32 (95% CI 2.05-2.65) for men, and 2.82 (95% CI 2.55-3.11) for women. Factors associated with mortality included: male gender, age ≥85, symptoms at the diagnosis, antipsychotic and systemic antibiotics treatment.
CONCLUSION
These findings emphasize the need of close and tailored monitoring of dementia patients to reduce the impact of COVID-19 on this fragile population.

Identifiants

pubmed: 35912744
pii: JAD220369
doi: 10.3233/JAD-220369
pmc: PMC9535569
doi:

Substances chimiques

Anti-Bacterial Agents 0
Antipsychotic Agents 0
Fibrinolytic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

681-693

Références

Lancet Psychiatry. 2020 Dec;7(12):1054-1063
pubmed: 33031760
Geriatr Nurs. 2021 Sep-Oct;42(5):983-992
pubmed: 34256158
Int J Environ Res Public Health. 2021 May 26;18(11):
pubmed: 34073437
Front Public Health. 2021 Jul 16;9:669209
pubmed: 34336767
Alzheimers Dement. 2021 Nov;17(11):1818-1831
pubmed: 33881211
J Alzheimers Dis. 2019;70(s1):S165-S186
pubmed: 31306123
Front Neurol. 2021 Jul 22;12:692662
pubmed: 34367054
Front Immunol. 2021 Aug 18;12:680845
pubmed: 34484179
Healthcare (Basel). 2021 Jul 15;9(7):
pubmed: 34356269
Alzheimers Dement. 2021 Aug;17(8):1297-1306
pubmed: 33559975
PLoS One. 2021 Feb 3;16(2):e0246548
pubmed: 33534870
Front Public Health. 2021 Aug 09;9:684112
pubmed: 34434913
Neurology. 2021 Apr 27;96(17):e2220-e2230
pubmed: 33741639
J Glob Health. 2021 Mar 01;11:10001
pubmed: 33767855
Lancet Reg Health Eur. 2022 Jan 10;14:100295
pubmed: 35036983
Aging Clin Exp Res. 2007 Oct;19(5):390-3
pubmed: 18007117
Respir Med. 2007 Sep;101(9):1845-63
pubmed: 17544265
Euro Surveill. 2020 May;25(19):
pubmed: 32431289
Lancet Psychiatry. 2021 Sep;8(9):797-812
pubmed: 34274033
Front Immunol. 2021 Aug 31;12:720952
pubmed: 34531867
Rev Neurol (Paris). 2022 Jan-Feb;178(1-2):129-136
pubmed: 34556345
J Neurol Sci. 2021 Sep 15;428:117610
pubmed: 34384971
Dement Geriatr Cogn Disord. 2021;50(5):425-436
pubmed: 34856552
Can J Psychiatry. 2017 Mar;62(3):170-181
pubmed: 28212496
Lancet Neurol. 2020 Nov;19(11):892
pubmed: 33098796
Int J Environ Res Public Health. 2021 Apr 06;18(7):
pubmed: 33917578
Lancet Public Health. 2022 Feb;7(2):e105-e125
pubmed: 34998485
Sci Rep. 2021 Jun 15;11(1):12530
pubmed: 34131216
Alzheimers Dement (Amst). 2020 Nov 14;12(1):e12114
pubmed: 33225041
Front Psychiatry. 2020 Oct 06;11:573367
pubmed: 33132936
Alzheimers Dement. 2020 Nov;16(11):1571-1581
pubmed: 32789951
J Alzheimers Dis. 2021;84(4):1447-1452
pubmed: 34690147
J Alzheimers Dis. 2020;78(4):1775-1782
pubmed: 33285638
Nat Commun. 2020 Dec 9;11(1):6317
pubmed: 33298944
Nat Rev Neurol. 2021 Feb;17(2):69-70
pubmed: 33408384
J Alzheimers Dis. 2021;84(3):1173-1181
pubmed: 34542068
J Alzheimers Dis Rep. 2018 Feb 2;2(1):1-26
pubmed: 30480245
Lancet. 2020 Apr 11;395(10231):1190-1191
pubmed: 32240625
J Gerontol A Biol Sci Med Sci. 2020 Oct 15;75(11):2224-2230
pubmed: 32687551
Int J Infect Dis. 2020 Oct;99:47-56
pubmed: 32721533
Public Health. 2021 Jan;190:108-115
pubmed: 33412438
Alzheimers Res Ther. 2021 Apr 10;13(1):77
pubmed: 33838684
PLoS One. 2020 Nov 17;15(11):e0241955
pubmed: 33201896
Lancet Public Health. 2018 Jul;3(7):e323-e332
pubmed: 29908859
EClinicalMedicine. 2020 Sep;26:100524
pubmed: 32864594
Infection. 2021 Feb;49(1):15-28
pubmed: 32860214
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652

Auteurs

Silvia Cascini (S)

Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.

Nera Agabiti (N)

Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.

Claudia Marino (C)

Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.

Anna Acampora (A)

Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.

Maria Balducci (M)

Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.

Enrico Calandrini (E)

Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.

Marina Davoli (M)

Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.

Anna Maria Bargagli (AM)

Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH